UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): February 15, 2017


 
WaferGen Bio-systems, Inc.
 
 
(Exact name of registrant as specified in its charter)
 

 
Nevada
 
000-53252
 
90-0416683
 
 
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
 

 
34700 Campus Drive, Fremont ,  CA
 
94555
 
 
(Address of principal executive offices)
 
(Zip Code)
 

(Registrant’s telephone number, including area code):   (510) 651-4450

Not Applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

þ
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))






Item 2.02.  Results of Operations and Financial Condition.


On February 15, 2017, WaferGen Bio-systems, Inc. announced preliminary financial results for the quarter and year ended December 31, 2016. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

The exhibit required to be filed as a part of this Current Report on Form 8-K is listed in the Exhibit Index attached hereto and incorporated herein by reference.




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.





WaferGen Bio-systems, Inc.




Date: February 15, 2017
By:
/s/ Michael P. Henighan
 
 
Michael P. Henighan
 
 
Chief Financial Officer

 

EXHIBIT INDEX

Exhibit No.
 
Description
 
 
 
99.1
 
Press release, dated February 15, 2017, issued by WaferGen Bio-systems, Inc., furnished herewith.
 
 
 



WaferGen Bio-Systems, Inc. (NASDAQ:WGBS)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024 WaferGen Bio-Systems, Inc. 차트를 더 보려면 여기를 클릭.
WaferGen Bio-Systems, Inc. (NASDAQ:WGBS)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024 WaferGen Bio-Systems, Inc. 차트를 더 보려면 여기를 클릭.